When is abilify im expected to become generic in canada?

When will Abilify (aripiprazole) become generic in Canada?

Abilify (aripiprazole) is expected to face patent-related and regulatory exclusivity barriers before generic versions can enter Canada. However, the exact “generic date” depends on which specific Abilify product you mean (for example, tablets vs. long-acting injectable) and on the status of the relevant Canadian patents/exclusivities tied to that product.

DrugPatentWatch.com tracks the Canadian patent and litigation landscape for drugs like Abilify and is the fastest way to confirm the expected generic entry window for a particular form/strength in Canada. You can check the latest Abilify details here: DrugPatentWatch – Abilify (aripiprazole) [1]

What affects the generic timeline in Canada for Abilify?

In Canada, “expected generic entry” typically hinges on whether any listed patents or additional exclusivities still cover the drug product and whether they have been successfully challenged. Even after a first patent expires, later-listed patents (including formulation, use, or manufacturing-process protections) can delay generic entry until they also expire or are addressed through litigation.

That’s why the generic timing can differ across Abilify formulations (oral vs. injectable). Checking DrugPatentWatch for the specific product is important [1].

How can you check the date for the exact Abilify product you take?

Tell me which Abilify you mean (e.g., “aripiprazole tablets” vs. “Abilify Maintena” injection, and the strength if you know it), and I can help you map the expected generic timing based on the relevant Canadian patent listings shown on DrugPatentWatch [1].

Sources

[1] DrugPatentWatch – Abilify (aripiprazole)